Protara Therapeutics, Inc. — Director's Dealing 2014

Oct 21, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2014-10-21

Reporting Person: Eldridge, George Arthur (Sr VP, CFO, Treasurer & Sec.)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$4.920	2024-06-23	Common Stock (81305)		Direct
Stock Option (Right to Buy)	$4.920	2024-06-23	Common Stock (44718)		Direct

Footnotes

F1: This option is fully exercisable prior to its vesting, subject to a repurchase right held by the Issuer on the shares underlying this option that lapses (based on the original option vesting schedule) 25% on the first anniversary of the grant date and the remaining shares in equal quarterly installments over the next three years.

F2: Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.